Aytu BioPharma Names Ryan Selhorn as CFO

Dow Jones

2024-11-14

By Stephen Nakrosis

Aytu BioPharma said Ryan Selhorn has been named as the company's chief financial officer, treasurer and corporate secretary, effective Nov. 11.

He succeeds Mark Oki as CFO. Oki will continue to consult for the company through Dec. 1.

Prior to being named CFO, Selhorn served as EVP, finance and business optimization, since November 2022, the company said. Before that, he was SVP, finance and operations, consumer healthcare division, and also served as VP, finance, consumer healthcare division.

Selhorn also served as VP and CFO at Innovus Pharmaceuticals, and as CFO and chief accounting officer of Signature Analytics, Aytu said.

Selhorn will receive an annual base salary of $400,000.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

November 13, 2024 18:53 ET (23:53 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2483864158"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2483864158\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2483864158?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-14 07:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483864158","market":"us","top_or_hot":-1,"title":"Aytu BioPharma Names Ryan Selhorn as CFO","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Aytu BioPharma said Ryan Selhorn has been named as the company's chief financial officer, treasurer and corporate secretary, effective Nov. 11. \n</p>\n<p>\n  He succeeds Mark Oki as CFO. Oki will continue to consult for the company through Dec. 1. \n</p>\n<p>\n  Prior to being named CFO, Selhorn served as EVP, finance and business optimization, since November 2022, the company said. Before that, he was SVP, finance and operations, consumer healthcare division, and also served as <a href=\"https://laohu8.com/S/VP..UK\">VP</a>, finance, consumer healthcare division. \n</p>\n<p>\n  Selhorn also served as VP and CFO at Innovus Pharmaceuticals, and as CFO and chief accounting officer of Signature Analytics, Aytu said. \n</p>\n<p>\n  Selhorn will receive an annual base salary of $400,000. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 13, 2024 18:53 ET (23:53 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aytu BioPharma Names Ryan Selhorn as CFO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAytu BioPharma Names Ryan Selhorn as CFO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-14 07:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Aytu BioPharma said Ryan Selhorn has been named as the company's chief financial officer, treasurer and corporate secretary, effective Nov. 11. \n</p>\n<p>\n  He succeeds Mark Oki as CFO. Oki will continue to consult for the company through Dec. 1. \n</p>\n<p>\n  Prior to being named CFO, Selhorn served as EVP, finance and business optimization, since November 2022, the company said. Before that, he was SVP, finance and operations, consumer healthcare division, and also served as <a href=\"https://laohu8.com/S/VP..UK\">VP</a>, finance, consumer healthcare division. \n</p>\n<p>\n  Selhorn also served as VP and CFO at Innovus Pharmaceuticals, and as CFO and chief accounting officer of Signature Analytics, Aytu said. \n</p>\n<p>\n  Selhorn will receive an annual base salary of $400,000. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 13, 2024 18:53 ET (23:53 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AYTU","symbol_name":"Aytu BioScience, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2483864158","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483864158","pubTimestamp":1731541980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Aytu BioPharma said Ryan Selhorn has been named as the company's chief financial officer, treasurer and corporate secretary, effective Nov. 11.He succeeds Mark Oki as CFO. Oki will continue to consult for the company through Dec. 1.Prior to being named CFO, Selhorn served as EVP, finance and business optimization, since November 2022, the company said. Before that, he was SVP, finance and operations, consumer healthcare division, and also served as VP, finance, consumer healthcare division.Selhorn also served as VP and CFO at Innovus Pharmaceuticals, and as CFO and chief accounting officer of Signature Analytics, Aytu said.Selhorn will receive an annual base salary of $400,000.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AYTU":"Aytu BioScience, Inc.","BK4007":"制药"},"translate_title":"Aytu BioPharma任命Ryan Selhorn为首席财务官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AYTU":0.9},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Aytu BioPharma said Ryan Selhorn has been named as the company's chief financial officer, treasurer and corporate secretary, effective Nov. 11. \n\n\n  He succeeds Mark Oki as CFO. Oki will continue to consult for the company through Dec. 1. \n\n\n  Prior to being named CFO, Selhorn served as EVP, finance and business optimization, since November 2022, the company said. Before that, he was SVP, finance and operations, consumer healthcare division, and also served as VP, finance, consumer healthcare division. \n\n\n  Selhorn also served as VP and CFO at Innovus Pharmaceuticals, and as CFO and chief accounting officer of Signature Analytics, Aytu said. \n\n\n  Selhorn will receive an annual base salary of $400,000. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2024 18:53 ET (23:53 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}